CHAIR
:
Thomas M. Gesell, PharmD (SCHNON), Development Director, Medical Affairs, Envision Pharma, Inc., United States
SPEAKER
(S):
Dannis Y. Chang,
PharmD (SPKNON), Medical Communications Scientist,
Genentech, A Member of the Roche Group, United States
Dannis Chang, PharmD, is a graduate of the USC School of Pharmacy and completed a post-doctoral oncology fellowship with Novartis in the field of US and Global Clinical Development and Scientific Affairs. He currently serves as a medical communications scientist at Genentech Inc.
|
Thomas M. Gesell, PharmD, Development Director, Medical Affairs, Envision Pharma, Inc., United States
Donna A. Holder, PharmD (SPKNON), Senior Director, Global MSL Excellence, AstraZeneca Pharmaceuticals, United States
Description
Provision of medical communication and medical liaison services within biopharmaceutical companies have existed in one form or another for about 50 years. Over the years, these services have been introduced to countries areas across the globe. With popularity comes the potential for regulation. This session will review some of the different types of medical communication and medical liaison models, review related regulatory guidelines in place, and discuss the implications for the globalization of medical communications and medical liaisons.